{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:54:09Z","timestamp":1778673249579,"version":"3.51.4"},"reference-count":68,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000923","name":"Australian Research Council Linkage Grant","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Novartis Pharmaceuticals Australia"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","cell.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.tips.2016.04.001","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T00:08:59Z","timestamp":1461974939000},"page":"498-507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Serelaxin: A Novel Therapeutic for Vascular Diseases"],"prefix":"10.1016","volume":"37","author":[{"given":"Chen Huei","family":"Leo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Jelinic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hooi Hooi","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Tare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura J.","family":"Parry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2016.04.001_bib0345","doi-asserted-by":"crossref","first-page":"R267","DOI":"10.1152\/ajpregu.00156.2011","article-title":"Maternal vasodilation during pregnancy: emerging role of relaxin","volume":"301","author":"Conrad","year":"2011","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.tips.2016.04.001_bib0350","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.semnephrol.2010.10.003","article-title":"Emerging role of relaxin in the maternal adaptations to normal pregnancy: implications for preeclampsia","volume":"31","author":"Conrad","year":"2011","journal-title":"Semin. Nephrol."},{"key":"10.1016\/j.tips.2016.04.001_bib0355","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0008-6363(02)00663-6","article-title":"Increased myocardial collagen and ventricular diastolic dysfunction in relaxin deficient mice: a gender-specific phenotype","volume":"57","author":"Du","year":"2003","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.tips.2016.04.001_bib0360","doi-asserted-by":"crossref","first-page":"9803","DOI":"10.1007\/s11357-015-9803-z","article-title":"Differential effects of relaxin deficiency on vascular aging in arteries of male mice","volume":"37","author":"Jelinic","year":"2015","journal-title":"Age"},{"key":"10.1016\/j.tips.2016.04.001_bib0365","doi-asserted-by":"crossref","first-page":"e107382","DOI":"10.1371\/journal.pone.0107382","article-title":"A vasoactive role for endogenous relaxin in mesenteric arteries of male mice","volume":"9","author":"Leo","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.tips.2016.04.001_bib0370","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)61855-8","article-title":"Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial","volume":"381","author":"Teerlink","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2016.04.001_bib0375","unstructured":"Metra, M. et al. (203) Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J. Am. Coll. Cardiol. 15, 196-206."},{"key":"10.1016\/j.tips.2016.04.001_bib0380","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cardfail.2009.01.008","article-title":"Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial","volume":"15","author":"Dschietzig","year":"2009","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.tips.2016.04.001_bib0385","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/eurheartj\/eht459","article-title":"A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure","volume":"35","author":"Ponikowski","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.tips.2016.04.001_bib0390","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1161\/HYPERTENSIONAHA.109.133926","article-title":"Unveiling the vasodilatory actions and mechanisms of relaxin","volume":"56","author":"Conrad","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.tips.2016.04.001_bib0395","doi-asserted-by":"crossref","first-page":"H285","DOI":"10.1152\/ajpheart.00786.2014","article-title":"Increased superoxide production and altered nitric oxide-mediated relaxation in the aorta of young but not old male relaxin-deficient mice","volume":"309","author":"Ng","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.tips.2016.04.001_bib0400","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1096\/fj.06-6263com","article-title":"Evidence for local relaxin ligand\u2013receptor expression and function in arteries","volume":"20","author":"Novak","year":"2006","journal-title":"FASEB J."},{"key":"10.1016\/j.tips.2016.04.001_bib0405","doi-asserted-by":"crossref","first-page":"R349","DOI":"10.1152\/ajpregu.00635.2001","article-title":"Myogenic reactivity is reduced in small renal arteries isolated from relaxin-treated rats","volume":"283","author":"Novak","year":"2002","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.tips.2016.04.001_bib0410","doi-asserted-by":"crossref","DOI":"10.1152\/ajpregu.00506.2015","article-title":"Relaxin deficiency attenuates pregnancy-induced adaptation of the mesenteric artery to angiotensin II in mice","author":"Marshall","year":"2016","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.tips.2016.04.001_bib0415","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1096\/fj.13-233429","article-title":"Localization of relaxin receptors in arteries and veins, and region-specific increases in compliance and bradykinin-mediated relaxation after in vivo serelaxin treatment","volume":"28","author":"Jelinic","year":"2014","journal-title":"FASEB J."},{"key":"10.1016\/j.tips.2016.04.001_bib0420","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1096\/fj.12-210567","article-title":"Relaxin mediates uterine artery compliance during pregnancy and increases uterine blood flow","volume":"26","author":"Vodstrcil","year":"2012","journal-title":"FASEB J."},{"key":"10.1016\/j.tips.2016.04.001_bib0425","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1096\/fj.13-230797","article-title":"Treatment for cerebral small vessel disease: effect of relaxin on the function and structure of cerebral parenchymal arterioles during hypertension","volume":"27","author":"Chan","year":"2013","journal-title":"FASEB J."},{"key":"10.1016\/j.tips.2016.04.001_bib0430","doi-asserted-by":"crossref","first-page":"e000493","DOI":"10.1161\/JAHA.113.000493","article-title":"Acute intravenous injection of serelaxin (recombinant human relaxin-2) causes rapid and sustained bradykinin-mediated vasorelaxation","volume":"3","author":"Leo","year":"2014","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.tips.2016.04.001_bib0435","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/bph.13404","article-title":"Time-dependent activation of prostacyclin and nitric oxide pathways during continuous intravenous infusion of serelaxin (recombinant human H2 relaxin)","volume":"173","author":"Leo","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tips.2016.04.001_bib0440","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.regpep.2005.09.009","article-title":"Acute and chronic effects of relaxin on vasoactivity, myogenic reactivity and compliance of the rat mesenteric arterial and venous vasculature","volume":"132","author":"Li","year":"2005","journal-title":"Regul. Pept."},{"key":"10.1016\/j.tips.2016.04.001_bib0445","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1161\/01.CIR.0000025630.05387.45","article-title":"Is the pregnancy hormone relaxin also a vasodilator peptide secreted by the heart?","volume":"106","author":"Fisher","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.tips.2016.04.001_bib0450","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1210\/en.2010-1126","article-title":"Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide","volume":"152","author":"McGuane","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.tips.2016.04.001_bib0455","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1530\/JOE-13-0115","article-title":"Relaxin induces rapid, transient vasodilation in the microcirculation of hamster skeletal muscle","volume":"218","author":"Willcox","year":"2013","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.tips.2016.04.001_bib0460","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1152\/japplphysiol.00845.2010","article-title":"Relaxin regulates vascular wall remodeling and passive mechanical properties in mice","volume":"111","author":"Debrah","year":"2011","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.tips.2016.04.001_bib0465","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/HYPERTENSIONAHA.109.149369","article-title":"Relaxin therapy reverses large artery remodeling and improves arterial compliance in senescent spontaneously hypertensive rats","volume":"55","author":"Xu","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.tips.2016.04.001_bib0685","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.pharmthera.2005.05.012","article-title":"\u2018Relaxin\u2019 the stiffened heart and arteries: the therapeutic potential for relaxin in the treatment of cardiovascular disease","volume":"112","author":"Samuel","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.tips.2016.04.001_bib0475","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/978-0-387-74672-2_6","article-title":"The vascular actions of relaxin","volume":"612","author":"Jeyabalan","year":"2007","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.tips.2016.04.001_bib0480","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11906-011-0231-x","article-title":"Effects of relaxin on arterial dilation, remodeling, and mechanical properties","volume":"13","author":"Conrad","year":"2011","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.tips.2016.04.001_bib0485","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1210\/en.2006-0989","article-title":"Vascular matrix metalloproteinase-9 mediates the inhibition of myogenic reactivity in small arteries isolated from rats after short-term administration of relaxin","volume":"148","author":"Jeyabalan","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.tips.2016.04.001_bib0490","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1161\/HYPERTENSIONAHA.110.165027","article-title":"Angiogenic growth factors are new and essential players in the sustained relaxin vasodilatory pathway in rodents and humans","volume":"57","author":"McGuane","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.tips.2016.04.001_bib0495","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1161\/01.RES.0000104086.43830.6C","article-title":"Essential role for vascular gelatinase activity in relaxin-induced renal vasodilation, hyperfiltration, and reduced myogenic reactivity of small arteries","volume":"93","author":"Jeyabalan","year":"2003","journal-title":"Circ. Res."},{"key":"10.1016\/j.tips.2016.04.001_bib0500","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1172\/JCI5630","article-title":"Relaxin is a potent renal vasodilator in conscious rats","volume":"103","author":"Danielson","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tips.2016.04.001_bib0505","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/pr.114.009472","article-title":"International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides","volume":"67","author":"Halls","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.tips.2016.04.001_bib0510","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1253\/circj.CJ-14-0014","article-title":"Therapeutic effects of serelaxin in acute heart failure","volume":"78","author":"Du","year":"2014","journal-title":"Circ. J."},{"key":"10.1016\/j.tips.2016.04.001_bib0515","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/ki.2013.518","article-title":"Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis","volume":"86","author":"Chow","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.tips.2016.04.001_bib0520","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1096\/fj.10-175471","article-title":"Relaxin causes selective outward remodeling of brain parenchymal arterioles via activation of peroxisome proliferator-activated receptor-\u03b3","volume":"25","author":"Chan","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.tips.2016.04.001_bib0525","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/01.RES.0000051884.27117.7E","article-title":"Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1\/2 and nuclear factor-kappaB","volume":"92","author":"Dschietzig","year":"2003","journal-title":"Circ. Res."},{"key":"10.1016\/j.tips.2016.04.001_bib0530","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1096\/fj.01-0070com","article-title":"The pregnancy hormone relaxin is a player in human heart failure","volume":"15","author":"Dschietzig","year":"2001","journal-title":"FASEB J."},{"key":"10.1016\/j.tips.2016.04.001_bib0535","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1210\/en.2004-1602","article-title":"Evidence against the hypothesis that endothelial endothelin B receptor expression is regulated by relaxin and pregnancy","volume":"146","author":"Kerchner","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.tips.2016.04.001_bib0690","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/bph.13371","article-title":"Enhanced serelaxin signalling in co-cultures of human primary endothelial and smooth muscle cells","volume":"173","author":"Sarwar","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tips.2016.04.001_bib0545","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/sj.bjp.0703393","article-title":"Endothelial dysfunction in diabetes","volume":"130","author":"De Vriese","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tips.2016.04.001_bib0550","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00424-010-0807-3","article-title":"Endothelial dysfunction in diabetes: multiple targets for treatment","volume":"459","author":"Ding","year":"2010","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.tips.2016.04.001_bib0555","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1476-5381.2008.00060.x","article-title":"Endothelium-dependent contractions in SHR: a tale of prostanoid TP and IP receptors","volume":"156","author":"Feletou","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tips.2016.04.001_bib0560","doi-asserted-by":"crossref","first-page":"H1609","DOI":"10.1152\/ajpheart.00360.2010","article-title":"Aging attenuates the vasodilator response to relaxin","volume":"300","author":"van Drongelen","year":"2011","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.tips.2016.04.001_bib0565","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1152\/japplphysiol.00470.2011","article-title":"Impaired vascular responses to relaxin in diet-induced overweight female rats","volume":"112","author":"van Drongelen","year":"2012","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.tips.2016.04.001_bib0570","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.peptides.2013.08.020","article-title":"Impaired effect of relaxin on vasoconstrictor reactivity in spontaneous hypertensive rats","volume":"49","author":"van Drongelen","year":"2013","journal-title":"Peptides"},{"key":"10.1016\/j.tips.2016.04.001_bib0575","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.12802","article-title":"Protection from cigarette smoke-induced vascular injury by recombinant human relaxin-2 (serelaxin)","author":"Pini","year":"2016","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.tips.2016.04.001_bib0580","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.phrs.2016.03.011","article-title":"Serelaxin (recombinant human relaxin-2) prevents high glucose-induced endothelial dysfunction by ameliorating prostacyclin production in the mouse aorta","volume":"107","author":"Ng","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.tips.2016.04.001_bib0585","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/cvr\/cvs149","article-title":"Relaxin improves TNF-\u03b1-induced endothelial dysfunction: the role of glucocorticoid receptor and phosphatidylinositol 3-kinase signalling","volume":"95","author":"Dschietzig","year":"2012","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.tips.2016.04.001_bib0590","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.regpep.2010.09.001","article-title":"Relaxin inhibits early steps in vascular inflammation","volume":"166","author":"Brecht","year":"2011","journal-title":"Regul. Pept."},{"key":"10.1016\/j.tips.2016.04.001_bib0595","doi-asserted-by":"crossref","first-page":"e75592","DOI":"10.1371\/journal.pone.0075592","article-title":"Relaxin protects rat lungs from ischemia\u2013reperfusion injury via inducible NO synthase: role of ERK-1\/2, PI3K, and forkhead transcription factor FKHRL1","volume":"9","author":"Alexiou","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.tips.2016.04.001_bib0600","first-page":"1367","article-title":"Relaxin protects against myocardial injury caused by ischemia and reperfusion in rat heart","volume":"152","author":"Bani","year":"1998","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.tips.2016.04.001_bib0605","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/jcmm.12120","article-title":"Acute treatment with relaxin protects the kidney against ischaemia\/reperfusion injury","volume":"17","author":"Collino","year":"2013","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.tips.2016.04.001_bib0610","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1042\/CS20130105","article-title":"Relaxin improves multiple markers of wound healing and ameliorates the disturbed healing pattern of genetically diabetic mice","volume":"125","author":"Bitto","year":"2013","journal-title":"Clin. Sci."},{"key":"10.1016\/j.tips.2016.04.001_bib0615","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.2337\/db13-0033","article-title":"Relaxin treatment reverses insulin resistance in mice fed a high-fat diet","volume":"62","author":"Bonner","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.tips.2016.04.001_bib0620","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/288373a0","article-title":"The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine","volume":"288","author":"Furchgott","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.tips.2016.04.001_bib0625","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/263663a0","article-title":"An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibit platelet aggregation","volume":"263","author":"Moncada","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.tips.2016.04.001_bib0630","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00424-010-0817-1","article-title":"Endothelium-derived hyperpolarising factors and associated pathways: a synopsis","volume":"459","author":"Edwards","year":"2010","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.tips.2016.04.001_bib0635","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/0090-6980(76)90047-2","article-title":"Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides","volume":"12","author":"Gryglewski","year":"1976","journal-title":"Prostaglandins"},{"key":"10.1016\/j.tips.2016.04.001_bib0640","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1152\/physrev.1999.79.4.1193","article-title":"Prostanoid receptors: structures, properties, and functions","volume":"79","author":"Narumiya","year":"1999","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.tips.2016.04.001_bib0645","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1748-1716.2009.01964.x","article-title":"Endothelial dysfunction and vascular disease","volume":"196","author":"Vanhoutte","year":"2009","journal-title":"Acta Physiol."},{"key":"10.1016\/j.tips.2016.04.001_bib0650","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/24388","article-title":"K+ is an endothelium-derived hyperpolarization factor in rat arteries","volume":"396","author":"Edwards","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.tips.2016.04.001_bib0655","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/j.1476-5381.1988.tb11752.x","article-title":"Acetylcholine releases endothelium-derived hyperpolarizing factor and EDRF from rat blood vessels","volume":"95","author":"Chen","year":"1988","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tips.2016.04.001_bib0660","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S0165-6147(02)02050-3","article-title":"EDHF: bringing the concepts together","volume":"23","author":"Busse","year":"2002","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.tips.2016.04.001_bib0665","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.tips.2006.12.007","article-title":"C-type natriuretic peptide: a new endothelium-derived hyperpolarizing factor?","volume":"28","author":"Sandow","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.tips.2016.04.001_bib0670","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/sj.bjp.0707222","article-title":"Effects of methyl beta-cyclodextrin on EDHF responses in pig and rat arteries; association between SKCa channels and caveolin-rich domians","volume":"151","author":"Absi","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tips.2016.04.001_bib0675","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1469-7580.2006.00647.x","article-title":"Spatial separation of endothelial small- and intermediate-conductance calcium-activated potassium channels (KCa) and connexins: possible relationship to vasodilator function?","volume":"209","author":"Sandow","year":"2006","journal-title":"J. Anat."},{"key":"10.1016\/j.tips.2016.04.001_bib0680","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1161\/01.RES.0000019756.88731.83","article-title":"Involvement of myoendothelial gap junctions in the actions of endothelium-derived hyperpolarizing factor","volume":"90","author":"Sandow","year":"2002","journal-title":"Circ. Res."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614716300025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614716300025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T10:35:12Z","timestamp":1621074912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614716300025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0165614716300025"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2016.04.001","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serelaxin: A Novel Therapeutic for Vascular Diseases","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2016.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}